Bahlinger V, Hartmann A, Eckstein M (2023)
Publication Type: Book chapter / Article in edited volumes
Publication year: 2023
Publisher: Humana Press Inc.
Edited Volumes: Urothelial Carcinoma - Methods and Protocols
Series: Methods in Molecular Biology
Book Volume: 2684
Pages Range: 249-255
DOI: 10.1007/978-1-0716-3291-8_15
Since 2016, the immunotherapeutic agents targeting PD-1 and PD-L1 are an integral part in first-line and second-line treatment of advanced or metastatic urothelial cancer. By PD-1 and PD-L1 inhibition with these drugs, the immune system is supposed to regain the capacity to actively kill cancer cells. Meanwhile, PD-L1 assessment is prescribed for patients not being eligible for platinum-based chemotherapy in first-line settings in metastatic disease (for monotherapy with atezolizumab or pembrolizumab) and for patients who are intended to receive adjuvant nivolumab treatment following radical cystectomy. Several challenges which are highlighted in this chapter affect PD-L1 testing in daily routine including availability of representative tissue materials, inter-observer variability, and different available PD-L1 immunohistochemistry assays with different analytical properties.
APA:
Bahlinger, V., Hartmann, A., & Eckstein, M. (2023). Assessment of PD-L1 Status in Urothelial Cancer. In Michèle J. Hoffmann, Nadine T. Gaisa, Roman Nawroth, Thorsten H. Ecke (Eds.), Urothelial Carcinoma - Methods and Protocols. (pp. 249-255). Humana Press Inc..
MLA:
Bahlinger, Veronika, Arndt Hartmann, and Markus Eckstein. "Assessment of PD-L1 Status in Urothelial Cancer." Urothelial Carcinoma - Methods and Protocols. Ed. Michèle J. Hoffmann, Nadine T. Gaisa, Roman Nawroth, Thorsten H. Ecke, Humana Press Inc., 2023. 249-255.
BibTeX: Download